Morningstar

Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

Provided by Dow Jones Jun 3, 2026, 1:08:00 PM

By Adriano Marchese

Arcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer.

The drug, casdatifan, will be added to two new arms of BMS's ROSETTA RCC-208 phase 1/2 study, which is testing pumitamig, an experimental two-in-one developed by BMS and BioNTech, both alone and in combination with other therapies to treat advanced renal cell carcinoma.

Each company keeps full rights to its own drug, and the collaboration is nonexclusive.

Arcus said that the collaboration is aimed at developing a new treatment approach that can keep kidney tumors under control for longer in a disease with few effective options.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 03, 2026 09:08 ET (13:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.

Tori Brovet Oct 1, 2026

14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark

Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options.

Russel Kinnel and Ivanna Hampton Oct 2, 2026

The Top Funds for a Simpler Retirement Portfolio

For retirement savers and retirees, Christine Benz highlights all-in-one funds and core funds that can serve as building blocks for a streamlined portfolio.

Christine Benz Sep 30, 2026

The 10 Best Dividend Stocks

These are the top dividend-paying stocks to buy today.

Susan Dziubinski Sep 29, 2026

10 Top-Performing US Dividend Stocks

Chevron and Pfizer are among Q3's high-yielding winners.

Bella Albrecht Oct 2, 2026

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.